The PCF Challenge Award funds multi-institutional teams pursuing high-risk, innovative team science investigations of metastatic, lethal prostate cancer — particularly studies with direct translational or clinical application. PCF seeks high-risk, currently unfunded projects from academic and community research institutions around the world and is willing to fund across a range of team sizes. The award complements the larger TACTICAL mechanism and focuses on accelerating breakthrough therapies, including correlative research tied to major clinical trials. Awards are multi-year and provide substantial direct support for ambitious collaborative research.
Eligibility Criteria:
- Teams of investigators from non-profit academic research centers; international applicants eligible
- Research must address metastatic, lethal prostate cancer; low-risk localized disease diagnostics/treatments are not competitive
- Basic, translational, computational, or clinical research accepted; team members need not have prior prostate cancer–specific training
- Cross-disciplinary, diverse teams are favored
- Currently unfunded projects only
Funding Details:
- Multi-year team award; amounts funded depend on level of innovation in applications received
- Indirect costs permitted per RFA terms
- Disbursement and reporting requirements outlined in the RFA
Deadline:
- Application submission deadline: March 16, 2026
- Submit via pcf.smartsimple.com; portal opened January 12, 2026
Where to Go for Further Information:
- RFAs page.
- Contact: researchgrants@pcf.org